BiotechTube

Orforglipron + Placebo

Phase 3Recruiting
0 views this week 0 watching⚡ Active💉Featured in GLP-1 & Metabolic Watch
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Obesity

Conditions

Obesity, Overweight, Type 2 Diabetes

Trial Timeline

May 15, 2025 → Aug 1, 2027

NCT ID
NCT06993792

About Orforglipron + Placebo

Orforglipron + Placebo is a phase 3 stage product being developed by Eli Lilly for Obesity. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06993792. Target conditions include Obesity, Overweight, Type 2 Diabetes.

What happened to similar drugs?

20 of 20 similar drugs in Obesity were approved

Approved (20) Terminated (5) Active (0)
✅exenatide + PlaceboEli LillyApproved
✅TirzepatideEli LillyApproved
✅Micafungin + MicafunginAstellas PharmaApproved
✅MicafunginAstellas PharmaApproved
✅Zonegran + PlaceboEisaiApproved
✅lorcaserin hydrochloride XR + PlaceboEisaiApproved
✅Placebo + TirzepatideEli LillyApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT07241390Phase 3Recruiting
NCT07223593Phase 3Recruiting
NCT07202884Phase 3Recruiting
NCT07153471Phase 3Recruiting
NCT06972472Phase 3Recruiting
NCT06972459Phase 3Recruiting
NCT06993792Phase 3Recruiting
NCT06952530Phase 3Recruiting
NCT06948435Phase 3Recruiting
NCT06948422Phase 3Recruiting
NCT06824051Phase 1Completed
NCT06672939Phase 3Recruiting
NCT06672549Phase 3Recruiting
NCT06649045Phase 3Active
NCT06584916Phase 3Completed
NCT06109311Phase 3Completed
NCT05971940Phase 3Completed
NCT05931380Phase 3Completed
NCT05869903Phase 3Active
NCT05872620Phase 3Completed

Competing Products

20 competing products in Obesity

See all competitors
ProductCompanyStageHype Score
MK0493MerckPhase 2
35
MK0557MerckPhase 3
40
AMG 786AmgenPhase 1
29
Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide PlaceboEli LillyPhase 2
39
TirzepatideEli LillyPhase 2
42
exenatide + PlaceboEli LillyApproved
43
BrenipatideEli LillyPhase 1
36
Orforglipron + PlaceboEli LillyPhase 3
47
TERN-601Terns PharmaceuticalsPhase 2
32
MBX 4291 + PlaceboMBX BiosciencesPhase 1
30
PG-102Rani TherapeuticsPhase 1
26
Orforglipron + PlaceboEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 3
40
Eloralintide + PlaceboEli LillyPhase 1
29
Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide PlaceboEli LillyPhase 2
27
LY3437943 + Midazolam + Warfarin + CaffeineEli LillyPhase 1
29
Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injectionSkye BiosciencePhase 2
29
TirzepatideEli LillyApproved
50
Adenosine + RegadenosonAstellas PharmaPre-clinical
26
Micafungin + MicafunginAstellas PharmaApproved
43